Cabazitaxel
Tubulin Inhibitor
DB06772
Approved Indication
For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
2
Targets
0
Resistance Mutations
3
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.
Details
DrugBank ID
DB06772 ↗
Approval Date
2010-06-17
Molecular Weight
835.9324 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01CD04
Synonyms
Cabazitaxelum, Taxoid XRP6258, TXD258
PubChem
CID: 9854073 ↗
ChEMBL
CHEMBL1201748 ↗
SMILES
[H][C@@](O)([C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O
ADMET Profile
Computing properties…
Drug References (DrugBank)